Joseph G. Pressey - Concepedia

Author

Joseph G. Pressey

Cincinnati Children's Hospital Medical Center ORCID

Also Known As

J Pressey, J.G. Pressey, Joseph G Pressey, Joseph G. Pressey, Joseph Gerald Pressey, Joseph Pressey, OLIE Study Investigators

155

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Cincinnati Children's Hospital Medical Center University of Alabama at Birmingham Children's of Alabama Dana-Farber Cancer Institute University of Michigan

About

Joseph G. Pressey is an author at Cincinnati Children's Hospital Medical Center specializing in medicine, pathology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	1.3K
2	Cell Biology	4	4	190
3	Health Sciences	2	2	178
4	Immunology	2	2	204
5	Natural Sciences	1	1	15

Joseph G. Pressey

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, The Lancet Oncology Tumor BiologyMedicineBasket StudyPathologyImmune Checkpoint Inhibitor	2020	383
Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 Pilar Ramos, Anthony N. Karnezis, David W. Craig, Nature Genetics Somatic VariantSomatic MutationsMedicineHypercalcemic TypeSmall Cell Carcinoma	2014	376
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors Mrinal M. Gounder, Ravin Ratan, Thierry Alcindor, New England Journal of Medicine	2023	213
Severe cytokine release syndrome in a patient receiving PD‐1‐directed therapy Seth J. Rotz, Daniel Leino, Sara Szabo, Pediatric Blood & Cancer ImmunologyPathologyImmune SystemSevere CrsImmunotherapy	2017	154
Selective activation-induced apoptosis of peripheral T cells imposed by macrophages. A potential mechanism of antigen-specific peripheral lymphocyte deletion David H. Munn, Joseph G. Pressey, Arthur C. Beall, The Journal of Immunology	1996	105
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes Lynn Lee, Anjelika Gasilina, Jayeeta Roychoudhury, JCI Insight	2017	94
GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis Ritesh K. Srivastava, Samer Z. Kaylani, Nayf Edrees, Oncotarget Alveolar Rhabdomyosarcoma GrowthEmbryonal RmsGli Inhibitor Gant-61OncologyMalignant Disease	2014	89
Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK Annmarie Ramkissoon, Katherine E. Chaney, David Milewski, Clinical Cancer Research	2019	77
Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: A report from the Children's Oncology Group Joseph G. Pressey, James R. Anderson, David K. Crossman, Pediatric Blood & Cancer	2011	73
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016) Brigitte C. Widemann, Yao Lu, Denise K. Reinke, Sarcoma	2019	73

Page 1